CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 97 filers reported holding CYTOSORBENTS CORP in Q3 2020. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,000 | -98.4% | 341 | -98.3% | 0.00% | – |
| Q1 2022 | $64,000 | -23.8% | 20,141 | 0.0% | 0.00% | – |
| Q4 2021 | $84,000 | -48.8% | 20,141 | -0.3% | 0.00% | – |
| Q3 2021 | $164,000 | -31.7% | 20,209 | -36.3% | 0.00% | – |
| Q2 2021 | $240,000 | -12.1% | 31,747 | +1.1% | 0.00% | – |
| Q1 2021 | $273,000 | -8.4% | 31,400 | -16.0% | 0.00% | – |
| Q4 2020 | $298,000 | +44.7% | 37,400 | +45.0% | 0.00% | – |
| Q3 2020 | $206,000 | -19.2% | 25,800 | 0.0% | 0.00% | – |
| Q2 2020 | $255,000 | +28.1% | 25,800 | 0.0% | 0.00% | – |
| Q1 2020 | $199,000 | +101.0% | 25,800 | 0.0% | 0.00% | – |
| Q4 2019 | $99,000 | -36.9% | 25,800 | -17.6% | 0.00% | – |
| Q3 2019 | $157,000 | +35.3% | 31,300 | +77.8% | 0.00% | – |
| Q2 2019 | $116,000 | -51.5% | 17,600 | -44.3% | 0.00% | – |
| Q1 2019 | $239,000 | -6.3% | 31,600 | 0.0% | 0.00% | – |
| Q4 2018 | $255,000 | -37.5% | 31,600 | 0.0% | 0.00% | – |
| Q3 2018 | $408,000 | +13.3% | 31,600 | 0.0% | 0.00% | – |
| Q2 2018 | $360,000 | – | 31,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 450,000 | $846,000 | 0.90% |
| Skylands Capital, LLC | 2,944,670 | $5,535,980 | 0.84% |
| Sargent Investment Group, LLC | 1,257,048 | $2,363,250 | 0.57% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 197,940 | $372,127 | 0.52% |
| Avenir Corp | 2,717,397 | $5,108,706 | 0.48% |
| Granahan Investment Management | 1,552,393 | $2,918,499 | 0.10% |
| Seelaus Asset Management LLC | 20,450 | $38,446 | 0.04% |
| HighMark Wealth Management LLC | 10,000 | $18,800 | 0.02% |
| Key Client Fiduciary Advisors, LLC | 13,000 | $24,440 | 0.02% |
| Eudaimonia Partners, LLC | 23,500 | $44,180 | 0.01% |